4.1 Review

beta-amyloid degradation and Alzheimer's disease

期刊

出版社

HINDAWI LTD
DOI: 10.1155/JBB/2006/58406

关键词

-

资金

  1. NIA NIH HHS [P01 AG014449, P01 AG003949, R01 AG010675] Funding Source: Medline
  2. NINDS NIH HHS [P50 NS040256] Funding Source: Medline
  3. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040256] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE ON AGING [P01AG003949, P01AG014449, R01AG010675] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Extensive beta-amyloid (A beta) deposits in brain parenchyma in the form of senile plaques and in blood vessels in the form of amyloid angiopathy are pathological hallmarks of Alzheimer's disease (AD). The mechanisms underlying A beta deposition remain unclear. Major efforts have focused on A beta production, but there is little to suggest that increased production of A beta plays a role in A beta deposition, except for rare familial forms of AD. Thus, other mechanisms must be involved in the accumulation of A beta in AD. Recent data shows that impaired clearance may play an important role in A beta accumulation in the pathogenesis of AD. This review focuses on our current knowledge of A beta-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE), insulin-degrading enzyme (IDE), angiotensin-converting enzyme (ACE), and the plasmin/uPA/tPA system as they relate to amyloid deposition in AD. Copyright (c) 2006 Deng-Shun Wang et al.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据